300 related articles for article (PubMed ID: 30822465)
1. CD26/DPP4 - a potential biomarker and target for cancer therapy.
Enz N; Vliegen G; De Meester I; Jungraithmayr W
Pharmacol Ther; 2019 Jun; 198():135-159. PubMed ID: 30822465
[TBL] [Abstract][Full Text] [Related]
2. Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4.
Lettau M; Dietz M; Vollmers S; Armbrust F; Peters C; Dang TM; Chitadze G; Kabelitz D; Janssen O
Cell Mol Life Sci; 2020 Feb; 77(4):751-764. PubMed ID: 31300870
[TBL] [Abstract][Full Text] [Related]
3. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.
Wagner L; Klemann C; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jun; 184(3):265-83. PubMed ID: 26671446
[TBL] [Abstract][Full Text] [Related]
4. CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context.
De Chiara L; Páez de la Cadena M; Rodríguez-Berrocal J; Alvarez-Pardiñas MC; Pardiñas-Añón MC; Varela-Calviño R; Cordero OJ
Dis Markers; 2020; 2020():4347936. PubMed ID: 32051696
[TBL] [Abstract][Full Text] [Related]
5. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
6. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Klemann C; Wagner L; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities.
Varela-Calviño R; Rodríguez-Quiroga M; Dias Carvalho P; Martins F; Serra-Roma A; Vázquez-Iglesias L; Páez de la Cadena M; Velho S; Cordero OJ
IUBMB Life; 2021 May; 73(5):761-773. PubMed ID: 33615655
[TBL] [Abstract][Full Text] [Related]
8. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
Jang JH; Janker F; De Meester I; Arni S; Borgeaud N; Yamada Y; Gil Bazo I; Weder W; Jungraithmayr W
Carcinogenesis; 2019 Apr; 40(2):324-334. PubMed ID: 30698677
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
10. Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice.
Jang JH; Baerts L; Waumans Y; De Meester I; Yamada Y; Limani P; Gil-Bazo I; Weder W; Jungraithmayr W
Clin Exp Metastasis; 2015 Oct; 32(7):677-87. PubMed ID: 26233333
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.
Matteucci E; Giampietro O
Curr Med Chem; 2009; 16(23):2943-51. PubMed ID: 19689275
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis.
Tasic T; Bäumer W; Schmiedl A; Schwichtenhövel F; Pabst R; Raap U; von Hörsten S; Stephan M
Clin Exp Allergy; 2011 Aug; 41(8):1098-107. PubMed ID: 21672052
[TBL] [Abstract][Full Text] [Related]
13. What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.
Elmansi AM; Awad ME; Eisa NH; Kondrikov D; Hussein KA; Aguilar-Pérez A; Herberg S; Periyasamy-Thandavan S; Fulzele S; Hamrick MW; McGee-Lawrence ME; Isales CM; Volkman BF; Hill WD
Pharmacol Ther; 2019 Jun; 198():90-108. PubMed ID: 30759373
[TBL] [Abstract][Full Text] [Related]
14. Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation.
Wagner L; Kaestner F; Wolf R; Stiller H; Heiser U; Manhart S; Hoffmann T; Rahfeld JU; Demuth HU; Rothermundt M; von Hörsten S
Neuropeptides; 2016 Jun; 57():21-34. PubMed ID: 26988064
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.
Amatya VJ; Takeshima Y; Kushitani K; Yamada T; Morimoto C; Inai K
Oncol Rep; 2011 Dec; 26(6):1369-75. PubMed ID: 21894438
[TBL] [Abstract][Full Text] [Related]
16. DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues.
Harstad EB; Rosenblum JS; Gorrell MD; Achanzar WE; Minimo L; Wu J; Rosini-Marthaler L; Gullo R; Ordway ND; Kirby MS; Chadwick KD; Cosma GN; Moyer CF
Regul Pept; 2013 Sep; 186():26-35. PubMed ID: 23850796
[TBL] [Abstract][Full Text] [Related]
17. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus.
Lee SA; Kim YR; Yang EJ; Kwon EJ; Kim SH; Kang SH; Park DB; Oh BC; Kim J; Heo ST; Koh G; Lee DH
J Clin Endocrinol Metab; 2013 Jun; 98(6):2553-61. PubMed ID: 23539735
[TBL] [Abstract][Full Text] [Related]
18. DPPIV/CD26: a tumor suppressor or a marker of malignancy?
Beckenkamp A; Davies S; Willig JB; Buffon A
Tumour Biol; 2016 Jun; 37(6):7059-73. PubMed ID: 26943912
[TBL] [Abstract][Full Text] [Related]
19. [Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule].
Morimoto C; Ohnuma K
Gan To Kagaku Ryoho; 2016 Jul; 43(7):855-62. PubMed ID: 27431629
[TBL] [Abstract][Full Text] [Related]
20. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview.
Bernstein HG; Keilhoff G; Dobrowolny H; Steiner J
Rev Neurosci; 2023 Jan; 34(1):1-24. PubMed ID: 35771831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
